These 2 Top Dividend Stocks Are Finally Rebounding, and There Might Be More Upside Ahead

The article identifies Apple and Eli Lilly as market leaders offering significant upside and robust dividend programs. Apple's Q3 FY25 results demonstrated 10% revenue and 12% EPS growth, fueled by an expanding device ecosystem and services, with new product cycles expected to sustain momentum. Eli Lilly, despite initial mixed trial data, rebounded strongly with promising Phase 3 results for its GLP-1 candidate orforglipron in diabetic patients and an even more potent pipeline asset in retatrutide, contributing to 38% Q2 revenue growth. Both companies present attractive long-term prospects for growth and income investors.

Analysis

Apple (AAPL) and Eli Lilly (LLY) are presented as large-cap leaders with distinct, compelling growth catalysts despite recent volatility. For Apple, strong Q3 FY25 results, including a 10% year-over-year revenue increase to $94 billion and a 12% rise in EPS to $1.57, underscore the power of its ecosystem. The company's base of over 2 billion active devices and 1 billion paid subscriptions is fueling growth in its high-margin services segment, providing a durable path to enhanced profitability. While concerns over AI strategy and tariffs exist, the market appears focused on the potential for a strong renewal cycle driven by the upcoming iPhone 17. Furthermore, Apple's capital return program is noteworthy; despite a low 0.4% forward yield, a 100% dividend increase over the past decade combined with a conservative 16% payout ratio signals significant capacity for future dividend growth. Eli Lilly has demonstrated resilience, rebounding 15% after initial investor disappointment over its oral GLP-1 candidate, orforglipron. The recovery was driven by subsequent strong Phase 3 data in diabetic patients and a head-to-head trial win against Novo Nordisk's Rybelsus, which should cement its market position. The company's pipeline appears robust, with retatrutide showing potential to surpass current treatments by inducing up to 24.2% weight loss in a Phase 2 study. This pipeline strength is reflected in the firm's exceptional 38% YoY revenue growth in Q2, indicating powerful momentum in the weight-loss market. Lilly's 200% dividend growth over ten years and a reasonable 44% payout ratio also position it as an attractive long-term holding for income-focused investors.

Key Decisions for Investors

• Investors with a long-term horizon could consider exposure to both Apple and Eli Lilly to capture distinct growth narratives in technology services and biopharmaceutical innovation.
• For Apple, focus should be on the adoption rate of the upcoming iPhone 17 and the continued margin expansion from the services segment, as these are the primary catalysts for future earnings and dividend growth, given its low 16% payout ratio.
• For Eli Lilly, it is critical to monitor upcoming Phase 3 data for retatrutide and the regulatory pathway for orforglipron, as continued pipeline execution is key to sustaining its 38% revenue growth trajectory and competitive edge against rivals like Novo Nordisk.